Search company, investor...
Search
YouScript company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

youscript.com

Stage

Incubator/Accelerator | Alive

Total Raised

$5.1M

About YouScript

YouScript uses genetic data and clinical knowledge on drug metabolism to help predict which prescription medications will work best for each patient. The YouScript Precision Prescribing Software is a comprehensive solution for safer, more targeted prescribing for every patient.On March 10th, 2020, YouScript was acquired by Invitae.3M.

YouScript Headquarters Location

108 S Jackson Street

Seattle, Washington, 98104,

United States

+1 206 829 4806

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing YouScript

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

YouScript is included in 6 Expert Collections, including Pharma Supply Chain.

P

Pharma Supply Chain

1,258 items

M

Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

D

Digital Health

13,114 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

10,176 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

B

Biopharma Tech

401 items

C

Clinical Encounter Tech

897 items

YouScript Patents

YouScript has filed 3 patents.

The 3 most popular patent topics include:

  • Clinical pharmacology
  • Amines
  • Combination drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/31/2019

4/12/2022

Genetics, Hepatotoxins, Clinical pharmacology, Combination drugs, Amines

Grant

Application Date

1/31/2019

Grant Date

4/12/2022

Title

Related Topics

Genetics, Hepatotoxins, Clinical pharmacology, Combination drugs, Amines

Status

Grant

Latest YouScript News

Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel

May 19, 2022

05/19/2022 | 06:31am EDT Message : *Required fields - New 38-gene testing panel and clinical decision support tool analyzes a patient's genetics and co-medications for their impact on drug and dose personalization - SAN FRANCISCO, May 19, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx) Panel which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool (CDST). With this launch, Invitae now has one of the most comprehensive commercially available PGx panels in the industry. In addition to mental health medications, the panel aligns with PGx-specific guidelines and published evidence that affects hundreds of commonly used medications, including frequently prescribed medications for high-risk patients in primary care, cardiology, endocrinology, pain management and oncology. Nearly one in four  patients has been prescribed medications for which they are predicted to have an atypical response due to their genetics. Given the compelling evidence that patient care can benefit from this information, PGx testing is poised to become the standard of care across all medical prescribing, utilizing both broad panels and specialized tests as available. However, accomplishing the goal of integrating PGx into standard of care requires more support for healthcare providers to recognize the utility of PGx testing and implement it in their practices. Major progress is being made at the state and federal level to remove barriers to adoption of PGx. Medicare local coverage determinations (LCDs) have rolled across the country aligning PGx testing coverage with the evidence. Congress also recently introduced the Right Drug Dose Now Act , which, if passed, would increase awareness of and access to PGx. States have also made moves to encourage the use of pharmacogenetics in clinical care; for example, legislation recently introduced in California is designed to align Medi-Cal coverage for pharmacogenomics with Food and Drug Administration (FDA) and Clinical Pharmacogenetics Implementation Consortium (CPIC) evidence. With the tools to successfully utilize PGx, providers can potentially reduce adverse drug effects, including side effects and treatment failures, save time, reduce costs and improve patient care. Invitae Pharmacogenomics Panel The Invitae Pharmacogenomics Panel includes 38 genes, covering the genes and variants affecting 98% of the medicines that according to CPIC and FDA can lead to an actionable major or moderate drug-gene interaction; this 98% figure does not include genes and variants that are ordinarily tested for diagnosis of specific diseases but may also impact drug therapy. Furthermore, access to Invitae's CDST, YouScript, is included with testing. YouScript is one of the most comprehensive medication management analytics and clinical decision support software offerings on the market employing over 17,000 curated references and product inserts to simulate a team of clinical pharmacists delivering real-time, evidence-based guidance. YouScript aids providers in mitigating the risk of potential drug-gene and drug-drug-gene interactions. A recent study  shows that using Invitae's YouScript Precision Prescribing Software and PGx testing reduce re-hospitalizations and emergency department visits by 52% and 42% respectively saving an estimated $4,382 per patient in 60 days. Considering that the U.S. spent an estimated $528 billion on non-optimized medications in 2016, exceeding the cost of the drugs themselves or any major chronic disease, making PGx testing and YouScript more widely available could result in substantial care improvements and cost reductions. "Ninety-nine percent of patients have genetic variants that can impact medication response making pharmacogenomics a foundational element for any precision medicine program," says Kristine Ashcraft, medical affairs director, pharmacogenomics at Invitae. "At Invitae, we pride ourselves on ease-of-use, so we offer both genetic testing and clinical decision support to enable clinicians to easily benefit from genetic insights when making prescription choices at the point of care." Invitae Pharmacogenomics Mental Health Panel  The panel aligns with some payer coverage that limits the number of genes covered for mental health. Psychiatrists and other doctors have been increasingly using PGx testing in mental health treatment because the majority of mental health medications have evidence-based PGx guidance and utilization of PGx in their patients has been shown to reduce the risk of side effects, lead to more rapid stabilization with reduced medication switching, and increase the chance that patients can successfully manage their conditions. Non-personalized prescribing can have serious consequences. One study  found that patients with unrecognized PGx variants significantly impacting response to es(citalopram) were victims of suicide 34.3% more often than individuals without variants affecting response to the drug. "In the U.S. alone, over 20% of adults take five or more medications every day and one of the most commonly prescribed drug types is antidepressants," continues Ashcraft. "This trend highlights the need to bring PGx testing into mainstream medical care, making it the standard, especially when treating polypharmacy patients and those with mental health conditions." To learn more about Invitae's expanded PGx testing, visit Invitae.com . About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices. For more information, visit the company's website at invitae.com . Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the availability, features and potential impact of the company's products; the company's belief that PGx testing is poised to become the standard of care across all medical prescribing; the company's beliefs regarding legislative progress to remove barriers to the adoption of PGx; and the potential benefits of PGx testing. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements. Contact:

YouScript Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

YouScript Rank

  • Where is YouScript's headquarters?

    YouScript's headquarters is located at 108 S Jackson Street, Seattle.

  • What is YouScript's latest funding round?

    YouScript's latest funding round is Incubator/Accelerator.

  • How much did YouScript raise?

    YouScript raised a total of $5.1M.

  • Who are the investors of YouScript?

    Investors of YouScript include Plug and Play Accelerator, Invitae and Genelex.

  • Who are YouScript's competitors?

    Competitors of YouScript include Nalagenetics and 2 more.

You May Also Like

OneOme Logo
OneOme

Oneome is a genomics interpretation company that exports pharmacogenomics knowledge in the form of concise, actionable reports to help providers deliver the right medication at the right time. Oneome focuses on providing pharmacogenomically driven guidance for medications with high levels of evidence in medical literature.

Coriell Life Sciences Logo
Coriell Life Sciences

Coriell Life Sciences provides genetic laboratory interpretation and reporting services. It offers a comprehensive medication safety solution and precise, gene-based diagnostic reporting.

Pillcheck Logo
Pillcheck

Pillcheck is a genomics-guided personalized medication management service that predicts how medications work, limiting potential side effects and helping individuals feel better, faster. Pillcheck’s proprietary Enterprise Platform connects healthcare providers and consumers while reducing exposure to unnecessary costs for payers.

GenXys Logo
GenXys

GenXys provides precision prescribing software and pharmacogenetic solutions to prevent adverse drug reactions, and personalize drug selection to increase drug efficacy. Powering every prescription with its software improves medication safety, increases drug efficacy and reduces healthcare costs. The company offers precision prescribing software and pharmacogenetic testing to healthcare organizations and employers looking to integrate personalized medicine into their benefits plans and license its technology to clinical laboratories.

Color Logo
Color

Color democratizes access to genetic information. The Color Test is physician-ordered and comes with complimentary board-certified genetic counseling for clients and healthcare providers. The 30-gene Color Test analyzes genes closely associated with some of the most common hereditary cancers: breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers.

Golden Helix Logo
Golden Helix

Golden Helix is a Bozeman, Montana-based bioinformatics company developing and redefining algorithms for detecting copy number variants and other structural variants from sequencing data in clinical contexts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.